Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748222 · ClinicalTrials.gov registry record · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
A Phase 3 study of Breast Cancer and Depression, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
- 20
- Study locations
NCT06748222 is a Phase 3 study of Breast Cancer and Depression that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 402 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06748222, a Phase 3 study of Breast Cancer and Depression, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
- 20
- Study locations
Study Summary
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Mindfulness (MAPs) Live Online
- BEHAVIORAL Mindfulness (MAPs) Digital App
- BEHAVIORAL Meditation Only Control Group
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
- Marshall Cancer Center - Cameron Park
- Enloe Medical Center - Chico
- UC Irvine Health Cancer Center-Newport - Costa Mesa
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Washington Hospital - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Fremont - Rideout Cancer Center - Marysville
- Kaiser Permanente- Modesto MOB II - Modesto
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Eisenhower Medical Center - Rancho Mirage
- Kaiser Permanente- Marshall Medical Offices - Redwood City
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2030-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748222
The ClinicalTrials.gov registry entry for NCT06748222 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Mindfulness (MAPs) Live Online is the first listed.
NCT06748222 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06748222 about?
NCT06748222 is a clinical study titled "E-Mindfulness Approaches for Living After Breast Cancer". NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wil...
What is the current status of trial NCT06748222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2025-06-12. Estimated completion is 2030-02-28.
What conditions does trial NCT06748222 study?
This clinical trial studies the following conditions: Breast Cancer, Depression.
What interventions are being tested in trial NCT06748222?
The interventions under investigation include: Mindfulness (MAPs) Live Online (BEHAVIORAL), Mindfulness (MAPs) Digital App (BEHAVIORAL), Meditation Only Control Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT06748222?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06748222 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.